BrugadaDrugs.org

We advice our patients to give the following letter, listing all the drugs on this website, to all of their health care professionals (including their general practitioner, dentist and pharmacist). Although the most appropriate treatment of Brugada syndrome is under discussion, avoidance of potentially proarrhythmic drugs and treatment of fever (which is a well-known trigger of cardiac events in Brugada syndrome) are generally accepted to be an important part of (prophylactic) treatment. However, some patients may (only) be appropriately treated with an implantable cardioverter-defibrillator. Some drugs may have an antiarrhythmic effect and may be used favorably in the acute or chronic setting (see potential antiarrhythmic drugs).

This patient letter has been translated into several languages by our colleagues. When you would appreciate to receive an email when the content of the letter is changed importantly (i.e. drugs added, removed or with changed qualification), please send us your update request here.

When your own language is currently not available, you may want to use the Google translation tool for this letter. You can find it here.

Click below on the language of your choice to download your patient letter.

Flag	Language	Translation	Date
	Catalan	Prof. J. Brugada, MD, PhD	July 2011
	Dutch	P.G. Postema, MD, PhD	July 2011
	English	P.G. Postema, MD, PhD	July 2011
	French	Prof. V. Probst, MD, PhD	July 2011
	German	C. Veltmann, MD	July 2011
	Hebrew	Prof. S. Viskin, MD	July 2011
	Italian	Prof. S.G. Priori, MD, PhD	July 2011
	Japanese	Prof. M. Hiraoka, MD, PhD / Y. Mizusawa, MD	July 2011
	Norwegian	Prof. K. Gjesdal, MD, PhD	July 2011
	Portuguese	A.R. Perez Riera, MD	July 2011
	Spanish	Prof. J. Brugada, MD, PhD	July 2011
	Swedish	Prof. L. Bergfeldt, MD, PhD	July 2011
	Thai	Prof. K. Nademanee, MD, PhD / Dr. G. Veerakul	July 2011